Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Entheon Biomedical Corp ENTBF


Primary Symbol: C.ENBI

Entheon Biomedical Corp. is a Canada-based biotechnology research and development company. The Company is focused on treating addiction and substance-use disorders.


CSE:ENBI - Post by User

Entheon Biomedical Corp
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(10)
•••
Post by Viralstocks1on Oct 27, 2021 11:47am
212 Views
Post# 34054664

Corporate Update on Studies and Clinical Trials

Corporate Update on Studies and Clinical TrialsNews Release (27-10-21): Entheon Biomedical Provides Corporate Update on Studies and Clinical Trials. Read here: https://finance.yahoo.com/news/entheon-biomedical-provides-corporate-studies-120000726.html
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities